FIELD: organic chemistry, medicine, oncology, pharmacy.
SUBSTANCE: invention relates to drugs and concerns a combination used in treatment of proliferative disease. The combination comprises 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine or its pharmaceutically acceptable salt, oxaliplatin and 5-fluorouracil wherein active components present in free form or in form of pharmaceutically acceptable salt in therapeutically effective doses in each case and optionally at least one pharmaceutically acceptable carrier, and this combination is used for separate or successive using. Also, invention discloses a pharmaceutical composition, method for treatment of proliferative disease and package for sale comprising 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine or its pharmaceutically acceptable salt, oxaliplatin and 5-fluorouracil.
EFFECT: improved method of treatment, valuable medicinal properties of agent.
7 cl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION COMPRISING N-{5-[4-(4-METHYLPIPERAZINOMETHYL)BENZOYLAMIDO]-2-METHYLPHENYL}-4-(3-PYRILYL)-2-PYRIDINEAMINE AND CHEMOTHERAPEURIC AGENT | 2002 |
|
RU2318517C2 |
| COMPOSITIONS CONTAINING SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | 2002 |
|
RU2333754C2 |
| COMBINATIONS CONTAINING EPOTHILONES AND ANTIMETABOLITES | 2003 |
|
RU2346686C2 |
| APPLICATION OF MEDICATIONS, BINDING EDG-RECEPTOR, IN TREATMENT OF CANCER DISEASE | 2008 |
|
RU2426555C2 |
| USE OF RAPAMYCIN DERIVATIVE | 2011 |
|
RU2483727C1 |
| APPLICATION OF EDG-RECEPTOR BINDING AGENT IN CANCER THERAPY | 2003 |
|
RU2358717C2 |
| APPLICATION OF RAPAMYCIN DERIVATIVE | 2013 |
|
RU2665138C2 |
| CANCER MEDICAL TREATMENT | 2005 |
|
RU2325906C2 |
| INHIBITION OR PREVENTION OF DISTURBED ANGIOGENIC REGULATION WITH USING RAPAMYCIN DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING RAPAMYCIN DERIVATIVE | 2006 |
|
RU2445093C2 |
| APPLICATION OF RAPAMYCIN DERIVATIVE | 2013 |
|
RU2659725C2 |
